1. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development
- Author
-
Joachim Lupberger, Thomas Baumert, Alessia Virzì, Simona Tripon, Victor Gonzalez-Motos, univOAK, Archive ouverte, Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), L'Institut hospitalo-universitaire de Strasbourg (IHU Strasbourg), Institut National de Recherche en Informatique et en Automatique (Inria)-l'Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD)-Les Hôpitaux Universitaires de Strasbourg (HUS)-La Fédération des Crédits Mutuels Centre Est (FCMCE)-L'Association pour la Recherche contre le Cancer (ARC)-La société Karl STORZ, Nouvel Hôpital Civil de Strasbourg, Institut Universitaire de France (IUF), and Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)
- Subjects
lcsh:Medicine ,Review ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Fibrosis ,medicine ,HBV ,Epigenetics ,HCC ,030304 developmental biology ,risk ,0303 health sciences ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,business.industry ,lcsh:R ,biomarkers ,General Medicine ,medicine.disease ,digestive system diseases ,cure ,3. Good health ,Chronic infection ,Hepatocellular carcinoma ,HCV ,Cancer research ,Biomarker (medicine) ,030211 gastroenterology & hepatology ,Signal transduction ,business ,Viral hepatitis ,liver disease ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Despite breakthroughs in antiviral therapies, chronic viral hepatitis B and C are still the major causes of liver fibrosis and hepatocellular carcinoma (HCC). Importantly, even in patients with controlled infection or viral cure, the cancer risk cannot be fully eliminated, highlighting a persisting oncogenic pressure imposed by epigenetic imprinting and advanced liver disease. Reliable and minimally invasive biomarkers for early fibrosis and for residual HCC risk in HCV-cured patients are urgently needed. Chronic infection with HBV and/or HCV dysregulates oncogenic and profibrogenic signaling within the host, also displayed in the secretion of soluble factors to the blood. The study of virus-dysregulated signaling pathways may, therefore, contribute to the identification of reliable minimally invasive biomarkers for the detection of patients at early-stage liver disease potentially complementing existing noninvasive methods in clinics. With a focus on virus-induced signaling events, this review provides an overview of candidate blood biomarkers for liver disease and HCC risk associated with chronic viral hepatitis and epigenetic viral footprints.
- Published
- 2021